About UsConflicting Demands

Increasing governmental regulation and enforcement by the U.S. Food and Drug Administration (FDA) has created new challenges and opportunities for innovation in the food, drug, cosmetics, and medical device industries. To offer strategic insights into the complexities of these challenges and prospects, Kilpatrick Townsend’s FDA Blog brings news and analysis on the latest legal developments so clients can effectively navigate this complex regulatory landscape throughout the lifecycle of their products — from development to marketing.

Kilpatrick Townsend’s FDA Regulatory Practice Group uses an integrated approach when providing effective and efficient legal services to FDA-regulated companies, including handling client matters before the Federal Trade Commission (FTC), Consumer Product Safety Commission (CSPC), and the National Advertising Division (NAD). Our multidisciplinary team provides comprehensive legal services, covering pharmaceuticals, over-the-counter drugs, and biologics; medical devices; foods and dietary supplements; cosmetics and personal care products; state and federal compliance; enforcement, imports, and inspections; congressional matters; and corporate due diligence in acquisitions, sales, or mergers of FDA-regulated entities or products.

More about our practice here : FDA Regulation

Latest Thinking

View more Insights
Insights Center
Knowledge assets are defined in the study as confidential information critical to the development, performance and marketing of a company’s core business, other than personal information that would trigger notice requirements under law. For example,
The new study shows dramatic increases in threats and awareness of threats to these “crown jewels,” as well as dramatic improvements in addressing those threats by the highest performing organizations. Awareness of the risk to knowledge assets increased as more respondents acknowledged that their